Patents by Inventor Roger Briesewitz

Roger Briesewitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170304383
    Abstract: Disclosed herein are novel compounds that are Ras inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In another aspect, provided is an antibody-drug-conjugate comprising an antibody conjugated with a compound described herein. In still another aspect, provided is a pharmaceutical composition comprising a compound or antibody-drug-conjugate described herein. In a further aspect, provided is method of treating a cancer comprising administering a therapeutically effective amount of a compound or antibody-drug-conjugate described herein to a patient in need thereof.
    Type: Application
    Filed: May 19, 2015
    Publication date: October 26, 2017
    Inventors: Roger BRIESEWITZ, Dehua PEI, Punit UPADHYAYA
  • Publication number: 20170112896
    Abstract: Disclosed herein are methods of inhibiting Rac or Rho in a cell or tissue or for treating a disease mediated at least in part by Rac or Rho, using a compound of the formula:
    Type: Application
    Filed: May 19, 2015
    Publication date: April 27, 2017
    Inventor: Roger BRIESEWITZ
  • Publication number: 20160333054
    Abstract: A method of inhibiting a binding event between a target protein and a binding protein, comprising administering to a cell in vitro an effective amount of a non-naturally occurring bifunctional inhibitor molecule including (a) protein binding moiety, and (b) an effector region, wherein the protein binding moiety binds to a blocking protein, and wherein the effector region binds to the target protein in order to bind the target protein and the blocking protein and prevent access of the binding protein to the target protein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: August 1, 2016
    Publication date: November 17, 2016
    Inventors: Roger Briesewitz, Dehua Pei, Xianghong Wu
  • Patent number: 9260484
    Abstract: A method of inhibiting a binding event between a target protein and a binding protein, comprising administering to a cell in vitro an effective amount of a non-naturally occurring bifunctional inhibitor molecule including (a) protein binding moiety, and (b) an effector region, wherein the protein binding moiety binds to a blocking protein, and wherein the effector region binds to the target protein in order to bind the target protein and the blocking protein and prevent access of the binding protein to the target protein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 16, 2016
    Assignee: Ohio State Innovation Foundation
    Inventors: Roger Briesewitz, Dehua Pei, Xianghong Wu
  • Publication number: 20140200186
    Abstract: A method of inhibiting a binding event between a target protein and a binding protein, comprising administering to a cell in vitro an effective amount of a non-naturally occurring bifunctional inhibitor molecule including (a) protein binding moiety, and (b) an effector region, wherein the protein binding moiety binds to a blocking protein, and wherein the effector region binds to the target protein in order to bind the target protein and the blocking protein and prevent access of the binding protein to the target protein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 15, 2012
    Publication date: July 17, 2014
    Inventors: Roger Briesewitz, Dehua Pei, Xianghong Wu
  • Patent number: 8044099
    Abstract: Bifunctional molecules and methods for their use are provided. The subject bifunctional molecules are conjugates of a drug moiety and a pharmacokinetic modulating moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit at least one modulated pharmacokinetic property upon administration to a host as compared to a free drug control. The subject bifunctional molecules find use in a variety of therapeutic applications.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 25, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roger Briesewitz, Gerald R. Crabtree, Thomas J. Wandless
  • Publication number: 20100112661
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Application
    Filed: August 26, 2009
    Publication date: May 6, 2010
    Applicant: THERAVANCE, INC.
    Inventors: Roger Briesewitz, John H. Griffin
  • Patent number: 7604944
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: October 20, 2009
    Assignee: Theravance, Inc.
    Inventors: Roger Briesewitz, John H. Griffin
  • Patent number: 7585653
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: September 8, 2009
    Assignee: Theravance, Inc.
    Inventors: Roger Briesewitz, John H. Griffin
  • Publication number: 20090087881
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Application
    Filed: February 15, 2007
    Publication date: April 2, 2009
    Inventors: Roger Briesewitz, John H. Griffin
  • Patent number: 7498025
    Abstract: Targeted bifunctional molecules and methods for their use are provided. The subject targeted bifunctional molecules are conjugates of a drug moiety and a targeting moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit a modulated biodistribution upon administration to a host as compared to a free drug control. The subject targeted bifunctional molecules find use in a variety of therapeutic applications.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: March 3, 2009
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roger Briesewitz, Gerald R. Crabtree, Thomas J. Wandless
  • Patent number: 7390784
    Abstract: Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. In the subject methods, an effective amount of the bifunctional molecule is administered to the host. The bifunctional molecule binds to the presenter protein to produce a binary complex that exhibits at least one of improved affinity, specificity or selectivity as compared to the corresponding free drug. The subject methods and compositions find use in a variety of therapeutic applications.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: June 24, 2008
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roger Briesewitz, Gerald R. Crabtree, Thomas Wandless, Gregory Thomas Ray, Kurt W. Vogel
  • Publication number: 20080102472
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Application
    Filed: December 11, 2007
    Publication date: May 1, 2008
    Inventors: Roger Briesewitz, John Griffin
  • Patent number: 7223783
    Abstract: Compounds of formula (I) in which R1, R2, R3 and R4 have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: May 29, 2007
    Assignee: Theravance, Inc.
    Inventors: John H. Griffin, Roger Briesewitz, Jonathan W. Wray
  • Patent number: 7220552
    Abstract: Bifunctional inhibitor molecules and methods for their use in the inhibition of protein—protein interactions are provided. The subject bifunctional inhibitor molecules are conjugates of a target protein ligand and a blocking protein ligand, where these two moieties are optionally joined by a linking group. In the subject methods, an effective amount of the bifunctional inhibitor molecule is administered to a host in which the inhibition of a protein—protein interaction is desired. The bifunctional inhibitor molecule simultaneously binds to its corresponding target and blocking proteins to produce a tripartite complex that inhibits the target protein—protein interaction. The subject methods and compositions find use in a variety of applications, including therapeutic applications.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: May 22, 2007
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerald R. Crabtree, Kryn Stankunas, Roger Briesewitz, Thomas J. Wandless
  • Patent number: 7195876
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: March 27, 2007
    Assignee: Theravance, Inc.
    Inventors: Roger Briesewitz, John H. Griffin
  • Publication number: 20060142281
    Abstract: Compounds of formula (I) in which R1, R2, R3 and R4 have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.
    Type: Application
    Filed: February 21, 2006
    Publication date: June 29, 2006
    Inventors: John Griffin, Roger Briesewitz, Jonathan Wray
  • Patent number: 7060703
    Abstract: Compounds of formula (I) in which R1, R2, R3 and R4 have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: June 13, 2006
    Assignee: Theravance, Inc.
    Inventors: John H. Griffin, Roger Briesewitz, Jonathan W. Wray
  • Publication number: 20050209265
    Abstract: Bifunctional molecules and methods for their use are provided. The subject bifunctional molecules are conjugates of a drug moiety and a pharmacokinetic modulating moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit at least one modulated pharmacokinetic property upon administration to a host as compared to a free drug control. The subject bifunctional molecules find use in a variety of therapeutic applications.
    Type: Application
    Filed: December 13, 2004
    Publication date: September 22, 2005
    Inventors: Roger Briesewitz, Gerald Crabtree, Thomas Wandless
  • Publication number: 20050209146
    Abstract: Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. In the subject methods, an effective amount of the bifunctional molecule is administered to the host. The bifunctional molecule binds to the presenter protein to produce a binary complex that exhibits at least one of improved affinity, specificity or selectivity as compared to the corresponding free drug. The subject methods and compositions find use in a variety of therapeutic applications.
    Type: Application
    Filed: December 13, 2004
    Publication date: September 22, 2005
    Inventors: Roger Briesewitz, Gerald Crabtree, Thomas Wandless, Gregory Ray, Kurt Vogel